Phosphorylation status of transcription factor C/EBPα determines cell-surface poly-LacNAc branching (I antigen) formation in erythropoiesis and granulopoiesis

Blood

Volumn 115, Issue 12, 2010, Pages 2491-2499

  Twu, Yuh Ching ^a   Hsieh, Chuang Yi ^a   Lin, Marie ^b   Tzeng, Cheng Hwai ^c,d   Sun, Chien Feng ^e,f   Yu, Lung Chih ^a,g  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

^g INSTITUTE OF BIOLOGICAL CHEMISTRY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP I ANTIGEN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN ALPHA SER 21; CD15 ANTIGEN; CD34 ANTIGEN; CD71 ANTIGEN; SERINE; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL SURFACE; CONTROLLED STUDY; ERYTHROID CELL; ERYTHROPOIESIS; GENE OVEREXPRESSION; GRANULOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; STEM CELL; VIRUS EXPRESSION;

EID: 77950592876     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-231993     Document Type: Article

References (50)

1. Watkins WM. Molecular basis of antigenic specificity in the ABO, H and Lewis blood-group systems. In: Montreuil J, Schachter H, Vliegenthart JFG, eds. Glycoproteins. Amsterdam, The Netherlands: Elsevier Science; 1995:313-390.
2. Hakomori S. Traveling for the glycosphingolipid path. Glycoconj J. 2000;17(7-9):627-647.
3. Watanabe K, Hakomori SI, Childs RA, Feizi T. Characterization of a blood group I-active ganglioside. J Biol Chem. 1979;254(9):3221-3228.
4. Fukuda M, Fukuda M, Hakomori S. Developmental change and genetic defect in the carbohydrate structure of band 3 glycoprotein of human erythrocyte membrane. J Biol Chem. 1979;254(10):3700-3703. (Pubitemid 9178781)
5. Piller F, Cartron J-P. Biosynthesis of blood group I antigens. J Biol Chem. 1984;259(21):13385-13390.
6. Issitt PD, Anstee DJ. Applied Blood Group Serology. Durham, NC: Montgomery Scientific Publications; 1998.
7. Daniels G. Human Blood Groups. Oxford, United Kingdom: Blackwell Science; 2002.
8. Wiener AS, Unger LJ, Cohen L, Feldman J. Type-specific cold auto-antibodies as a cause of acquired hemolytic anemia and hemolytic transfusion reactions: biological test with bovine red cells. Ann Intern Med. 1956;44(2):221-240.
9. Marsh WL, Jenkins WJ. Anti-i: a new cold antibody. Nature. 1960;188:753.
10. Marsh WL. Anti-i: a cold antibody defining the Ii relationship in human red cells. Br J Haemat. 1961;7:200-209.
11. Reid ME, Lomas-Francis C. The Blood Group Antigen FactsBook. San Diego, CA: Academic Press; 2004.
12. Marsh WL, Nichols ME, Reid ME. The definition of two I antigen components. Vox Sang. 1971;20(3):209-217.
13. Giblett ER, Crookston MC. Agglutinability of red cells by anti-i in patients with thalassæmia major and other hæmatological disorders. Nature. 1964;201:1138-1139.
14. Bierhuizen MFA, Mattei M-G, Fukuda M. Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N- acetylglucosaminyltransferase gene family. Genes Dev. 1993;7(3):468-478. (Pubitemid 23139239)
15. Yu LC, Twu YC, Chou ML, et al. The molecular genetics of the human I locus and molecular background explain the partial association of the adult i phenotype with congenital cataracts. Blood. 2003;101(6):2081-2088.
16. Inaba N, Hiruma T, Togayachi A, et al. A novel I-branching β-1,6-N-acetylglucosaminyltransferase involved in human blood group I antigen expression. Blood. 2003;101(7):2870-2876. (Pubitemid 36857656)
17. Yu LC, Twu YC, Chang CY, Lin M. Molecular basis of the adult i phenotype and the gene responsible for the expression of the human blood group I antigen. Blood. 2001;98(13):3840-3845. (Pubitemid 37391936)
18. Twu Y-C, Chen C-P, Hsieh C-Y, et al. I branching formation in erythroid differentiation is regulated by transcription factor C/EBPα. Blood. 2007;110(13):4526-4534.
19. Tenen DG, Hromas R, Licht JD, Zhang D-E. Transcription factors, normal myeloid development, and leukemia. Blood. 1997;90(2):489-519. (Pubitemid 27299089)
20. Mueller BU, Pabst T. C/EBPα and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol. 2006;13(1):7-14. (Pubitemid 43755840)
21. Twu Y-C, Hsieh C-Y, Yu L-C. Expression of the histo-blood group B gene predominates in ABgenotype cells. Transfusion. 2006;46(11):1988-1996.
22. Ausubel FM, Brent R, Kingston RE, et al. Current Protocols in Molecular Biology. Hoboken, NJ: John Wiley & Sons; 1998.
23. Ross SE, Radomska HS, Wu B, et al. Phosphorylation of C/EBPα inhibits granulopoiesis. Mol Cell Biol. 2004;24(2):675-686.
24. Radomska HS, Basseres DS, Zheng R, et al. Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. J Environ Monit. 2006;203(2):371-381. (Pubitemid 43290846)
25. Ross SE, Erickson RL, Hemati N, MacDougald OA. Glycogen synthase kinase 3 is an insulin-regulated C/EBPα kinase. Mol Cell Biol. 1999;19(12):8433-8441. (Pubitemid 30414037)
26. Wang G-L, Iakova P, Wilde M,Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBPα growth inhibitory activity. Genes Dev. 2004;18(8):912-925. (Pubitemid 38529660)
27. Behre G, Singh SM, Liu H, et al. Ras signaling enhances the activity of C/EBPα to induce granulocytic differentiation by phosphorylation of serine 248. J Biol Chem. 2002;277(29):26293-26299. (Pubitemid 34967120)
28. Testa U, Henri A, Bettaieb A, et al. Regulation of i- and I-antigen expression in the K562 cell line. Cancer Res. 1982;42(11):4694-4700. (Pubitemid 13205975)
29. Andersson LC, Jokinen M, Gahmberg CG. Induction of erythroid differentiation in the human leukemia cell line K562. Nature. 1979;278:364-365. (Pubitemid 9124381)
30. Rutherford TR, Clegg JB, Weatherall DJ. K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. Nature. 1979;280:164-165.
31. Zhang D-E, Zhang P, Wang N-D, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc Natl Acad Sci U S A. 1997;94(2):569-574. (Pubitemid 27053674)
32. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002;365(Pt 3):561-575. (Pubitemid 34864439)
33. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci. 2005;118(Pt 12):2545-2555.
34. D'Alo' F, Johansen LM, Nelson EA, et al. The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells. Blood. 2003;102(9):3163-3171. (Pubitemid 37314752)
35. Zhang P, Iwasaki-Arai J, Iwasaki H, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα. Immunity. 2004;21(6):853-863. (Pubitemid 39642186)
36. Mahoney CW, Shuman J, McKnight SL, Chen H-C, Huang K-P. Phosphorylation of CCAAT-enhancer binding protein by protein kinase C attenuates site-selective DNA binding. J Biol Chem. 1992;267(27):19396-19403.
37. Wang G-L, Shi X, Saliabury E, et al. Cyclin D3 maintains growth-inhibitory activity of C/EBPα by stabilizing C/EBPα-cdk2 and C/EBPα-Brm complexes. Mol Cell Biol. 2006;26(7):2570-2582.
38. Singh SM, Trivedi AK, Behre G. C/EBPα S248A mutation reduces granulocytic differentiation in human leukemia K562 cells. Biochem Biophys Res Commun. 2008;369(2):692-694.
39. Levy JE, Jin O, Fujiwara Y, Kuo F, Andrews NC. Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet. 1999;21(4):396-399. (Pubitemid 29159576)
40. Rosenfield RE. A-B hemolytic disease of the newborn: analysis of 1480 cord blood specimens, with special reference to the direct antiglobulin test and to the group O mother. Blood. 1955;10(1):17-28.
41. Klinman NR, Karush F. Equine anti-hapten antibody. V. The non-precipitability of bivalent antibody. Immunochemistry. 1967;4(6):387-405.
42. Hornick CL, Karush F. Antibody affinity. III. The role of multivalence. Immunochemistry. 1972;9(3):325-340.
43. Gopalakrishnan PV, Karush F. Antibody affinity. VII. Multivalent interaction of anti-lactoside antibody. J Immunol. 1974;113(3):769-778.
44. Romans DG, Tilley CA, Dorrington KJ. Monogamous bivalency of IgG antibodies. I. Deficiency of branched ABHI-active oligosaccharide chains on red cells of infants causes the weak antiglobulin reactions in hemolytic disease of the newborn due to ABO incompatibitity. J Immunol. 1980;124(6):2807-2811.
45. Muramatsu H, Kusano T, Sato M, Oda Y, Kobori K, Muramatsu T. Embryonic stem cells deficient in I β1,6-N-acetylglucosaminyltransferase exhibit reduced expression of embryoglycan and the loss of a Lewis X antigen, 4C9. Glycobiology. 2008;18(3):242-249. (Pubitemid 351359691)
46. Hakomori S-I, Kannagi R. Glycosphingolipids as tumor-associated and differentiation markers. J Natl Cancer Inst. 1983;71(2):231-251.
47. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood. 2000;95(7):2391-2396. (Pubitemid 30167741)
48. Witt O, Monkemeyer S, Rönndahl G, et al. Induction of fetal hemoglobin expression by the histon deacetylase inhibitor apicidin. Blood. 2003;101(6):2001-2007. (Pubitemid 36237607)
49. Pace BS, Qian X-H, Sangerman J, et al. p38 MAP kinase activation mediates γ-globin gene induction in erythroid progenitors. Exp Hematol. 2003;31(11):1089-1096. (Pubitemid 37329753)
50. Qiao L, MacDougald OA, Shao J. CCAAT/enhancer-binding protein α mediates induction of hepatic phosphoenolpyruvate carboxykinase by p38 mitogen-activated protein kinase. J Biol Chem. 2006;281(34):24390-24397. (Pubitemid 44274211)